ERBB2 and breast cancer: Moreover, the P-RAD (NCT04443348) trial studies the efficacy of neoadjuvant RT plus pembrolizumab followed by concurrent chemotherapy and pembrolizumab in HER2- patients [77], while the BreastVAX (NCT04454528) is recruiting patients with early BC that will be submitted to preoperative RT with a single 7 Gy fraction and pembrolizumab IO [78].